PMID- 19674256
OWN - NLM
STAT- MEDLINE
DCOM- 20101104
LR  - 20151119
IS  - 1743-6109 (Electronic)
IS  - 1743-6095 (Linking)
VI  - 6
IP  - 10
DP  - 2009 Oct
TI  - Timing of dose relative to sexual intercourse attempt in previous sildenafil 
      citrate users treated with tadalafil: a geographical comparison from a single 
      arm, open-label study.
PG  - 2836-50
LID - 10.1111/j.1743-6109.2009.01413.x [doi]
AB  - INTRODUCTION: Previous research has demonstrated that sildenafil citrate users 
      alter dosing-sexual attempt behavior when switched to tadalafil. The impact of 
      geography and culture on sexual behavior with phosphodiesterase type 5 (PDE5) 
      inhibitor treatment has not been fully investigated. AIM: To describe and compare 
      the changes in dosing-sexual attempt behavior with sildenafil citrate vs. 
      tadalafil treatment across four distinct geographies: Asia, Australia/New Zealand 
      (ANZ), Central Eastern Europe/Middle East (CEE/ME), and Latin America (LA). 
      METHODS: Data from a single-arm, open-label clinical trial conducted in 21 
      countries from November 2002 to May 2004 were used in this analysis. Men with 
      erectile dysfunction and a history of > or =6-week prior sildenafil citrate use 
      continued sildenafil citrate treatment for 4 weeks then switched to tadalafil for 
      8 weeks. Dosing instructions were provided. MAIN OUTCOMES MEASURES: Timing of 
      dose and sexual intercourse was assessed through patient diaries for the final 4 
      weeks of each treatment period. RESULTS: A total of 2,760 men were enrolled: Asia 
      15.8%; ANZ 29.4%; CEE/ME 19.7%; LA 35.1%. The median time from dosing to 
      intercourse was significantly increased during tadalafil treatment across all 
      geographical regions; however, the magnitude of increase differed significantly 
      by geography (P < 0.0001). The Asian cohort demonstrated the shortest duration 
      between dosing and sexual intercourse attempts (irrespective of drug), and 
      altered sexual behavior the least upon switching to tadalafil. The ANZ cohort 
      demonstrated the longest duration between dosing and sexual intercourse attempts 
      (irrespective of drug), and altered sexual behavior the most upon switching to 
      tadalafil. CONCLUSION: Men with a history of established sildenafil citrate use 
      alter their dose-attempt behavior when treated with tadalafil irrespective of 
      geography. However, the extent to which sexual behavior alters is not uniform 
      across geographical regions, suggesting that dosing instructions and duration of 
      drug effectiveness, in combination with personal and cultural preferences, may 
      determine sexual behavior with PDE5 inhibitor use.
FAU - Rubio-Aurioles, Eusebio
AU  - Rubio-Aurioles E
AD  - Asociacion Mexicana para la Salud Sexual A.C.-AMSSAC, Mexico City, Mexico.
FAU - Glina, Sidney
AU  - Glina S
FAU - Abdo, Carmita H N
AU  - Abdo CH
FAU - Hernandez-Serrano, Ruben
AU  - Hernandez-Serrano R
FAU - Rampazzo, Claudia
AU  - Rampazzo C
FAU - Sotomayor, Mariano
AU  - Sotomayor M
FAU - West, Teena M
AU  - West TM
FAU - Gallagher, Gabrielle L
AU  - Gallagher GL
FAU - Lenero, Enrique
AU  - Lenero E
LA  - eng
PT  - Clinical Trial
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20090811
PL  - Netherlands
TA  - J Sex Med
JT  - The journal of sexual medicine
JID - 101230693
RN  - 0 (Carbolines)
RN  - 0 (Phosphodiesterase Inhibitors)
RN  - 0 (Piperazines)
RN  - 0 (Purines)
RN  - 0 (Sulfones)
RN  - 742SXX0ICT (Tadalafil)
RN  - BW9B0ZE037 (Sildenafil Citrate)
SB  - IM
MH  - Analysis of Variance
MH  - Asia
MH  - Australia
MH  - Carbolines/*therapeutic use
MH  - *Coitus
MH  - Confidence Intervals
MH  - Europe
MH  - Geography
MH  - Health Status Indicators
MH  - Humans
MH  - Impotence, Vasculogenic/*drug therapy
MH  - Latin America
MH  - Male
MH  - Middle Aged
MH  - Middle East
MH  - New Zealand
MH  - Patient Satisfaction
MH  - Phosphodiesterase Inhibitors/*therapeutic use
MH  - Piperazines/*therapeutic use
MH  - Purines/therapeutic use
MH  - Sildenafil Citrate
MH  - Sulfones/*therapeutic use
MH  - Tadalafil
MH  - Time Factors
EDAT- 2009/08/14 09:00
MHDA- 2010/11/05 06:00
CRDT- 2009/08/14 09:00
PHST- 2009/08/14 09:00 [entrez]
PHST- 2009/08/14 09:00 [pubmed]
PHST- 2010/11/05 06:00 [medline]
AID - S1743-6095(15)32282-7 [pii]
AID - 10.1111/j.1743-6109.2009.01413.x [doi]
PST - ppublish
SO  - J Sex Med. 2009 Oct;6(10):2836-50. doi: 10.1111/j.1743-6109.2009.01413.x. Epub 
      2009 Aug 11.